VIVES is a multi-sector fund that invests in projects with a positive societal impact
The Akkermansia company is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (BE) and the University of Wageningen (NL). It...
Viridaxis is a specialist in development and supply of efficient and effective natural aphid control methods for the agricultural sector. Their R&D activities include applied field research to...
Keemotion has developed a motion detection technology. Their proprietary software offers a complete solution for coaches, leagues and broadcasters. Thanks to Keemotion, your organization produces...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
David Frenay, CEO Emolytics:
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is